The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 30, 2023. Its latest SEC filing is a SC 13G/A from May 8, 2023.
10-K for FY2022, filed Mar 30, 2023
The sections below describe the company as of the FY2022 annual report.
Sells endoscopic suturing and tacking systems and intragastric balloons for gastroenterologists and bariatric surgeons treating gastrointestinal conditions and obesity.
10-K for FY2022, filed Mar 30, 2023We are a medical technology company primarily focused on the design, development and commercialization of next-generation, less invasive…View ↗
Our Endoscopy product portfolio consists of the OverStitch® Endoscopic Suturing System, X-Tack® Endoscopic HeliX Tacking System, Apollo…View ↗
Our products are primarily used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal…View ↗
Sells products to healthcare providers and distributors, who generally pay under specified terms after the products ship. Distributors owe payment whether or not they have resold the products.
10-K for FY2022, filed Mar 30, 2023The Company’s principal source of revenues is from the sale of its products. Revenue is recognized when control of the promised goods is…View ↗
$76.9M
10-K for FY2022, filed Mar 31, 2023
$76.9M ↗
Sells mainly to hospitals, outpatient surgical centers, clinics and physicians through its own sales force in the U.S., Australia and certain European countries; in other markets where it has regulatory clearance but no employees, it sells through distributors.
10-K for FY2022, filed Mar 30, 2023Sales and DistributionView ↗
No. It lost $39.8M in FY2022.
10-K for FY2022, filed Mar 31, 2023
−$31.4MView ↗
10-K for FY2022, filed Mar 31, 2023
−$39.8MView ↗
10-K for FY2022, filed Mar 31, 2023
−$33.5MView ↗
8-K, filed Apr 4, 2023
As described in the Introductory Note of this Current Report on Form 8-K, on April 4, 2023, the Merger was completed. Upon the consummation…View ↗
Grew. Revenue grew 26% in 4 years, from $60.9M in FY2018 to $76.9M in FY2022, about 6% a year.
Broader endoscopy product line
The older report centered the endoscopy portfolio on OverStitch and Orbera; the latest report also includes X-Tack and Apollo ESG and REVISE systems.
10-K for FY2019, filed Mar 26, 2020 10-K for FY2022, filed Mar 30, 2023Our strategic focus and our future revenue growth is expected to come from our Endoscopy product portfolio, which consists of the…View ↗
Our Endoscopy product portfolio consists of the OverStitch® Endoscopic Suturing System, X-Tack® Endoscopic HeliX Tacking System, Apollo…View ↗
Competes with Boston Scientific, Olympus Medical, Endo Tools Therapeutics, Steris, Cook Medical, Endomina, USGI Medical, EndoTools, SC MedSil, Medicone, Allurion Technologies, Spatz Laboratories, ReShape Lifesciences, Spatz FGIA, Johnson & Johnson, and Medtronic
10-K for FY2022, filed Mar 30, 2023We are the leading manufacturer of devices for full thickness endoscopic suturing currently on the market in the U.S. or outside the U.S.…View ↗
Loading...
